Comparative Pharmacology
Head-to-head clinical analysis: CIPRO HC versus DIFICID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO HC versus DIFICID.
CIPRO HC vs DIFICID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription; hydrocortisone suppresses inflammation via glucocorticoid receptor activation.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
Instill 3 drops into the affected ear(s) twice daily (morning and evening) for 7 days.
200 mg (tablet) orally twice daily for 10 days.
None Documented
None Documented
Ciprofloxacin: 4-6 hours (prolonged to 6-9 hours in elderly or renal impairment). Hydrocortisone: 1-2 hours.
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Ciprofloxacin: ~50-70% excreted renally as unchanged drug, ~15% as metabolites; ~20-30% eliminated via biliary/fecal route. Hydrocortisone: metabolized hepatically, renal excretion of metabolites.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Category C
Category C
Antibiotic/Corticosteroid Combination (Otic)
Antibiotic